IND status for MGB Biopharma’s CDAD drug
The Food and Drug Administration (FDA) and Health Canada have cleared Investigational New Drug applications (IND) for MGB Biopharma’s lead candidate MGB-BP-3, for the treatment of clostridium difficile-associated diarrhoea.
Read More
